Skip to main content

A Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of ARGX-117 in Improving Allograft Function in Recipients of a Deceased Donor Renal Allograft at Risk for Delayed Graft Function

Open
  • Protocol code: ARGX-117-2201
  • EudraCT code: 2022-503091-89-00
  • Research group: Nephrology and kidney transplantation
  • Service: Nephrology
  • Principal investigator:  Moreso Mateos, Francesc
  • Phase: Fase II
  • Status: Recruiting volunteers